Agendia Appoints Dr. Stefan Glück to Chair Medical Advisory Board

Publication Name: Press Release

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 9, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Stefan Glück, MD, PhD, will lead the company’s Medical Advisory Board. As Chairman, Dr. Glück … Continued

Agendia Welcomes Dr. Mark Gittleman to Expanding Medical Advisory Board

Publication Name: Press Release

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, July 10, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that Dr. Mark Gittleman, Medical Director of Breast Care Specialists and Advanced Breast Care Imaging, has … Continued

Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction

Publication Name: Press Release

Agendia’s Microarray-based Gene Expression Profile Provides Critical Additional Information for Treatment Decisions for Stage II Colon Cancer Patients IRVINE, CA and AMSTERDAM, THE NETHERLANDS, June 1, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, … Continued

Agendia Raises $65 Million in a Private Round of Equity Financing

Publication Name: Press Release

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, May 31, 2012 – Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, today announced that the company has raised USD $65 million in a private round of equity financing. “The … Continued

RASTER: First-Ever Prospective Diagnostic Study in Breast Cancer

Publication Name: Press Release

RASTER Five-Year Follow-Up Data Indicates Chemotherapy May Be Safely Withheld for Patients Deemed ‘Low Risk’ for Breast Cancer Recurrence Using Agendia’s MammaPrint Test, Data Presented at European Breast Cancer Conference IRVINE, CA and AMSTERDAM, THE NETHERLANDS, March 22, 2012 – … Continued

Agendia Wins 2011 Scrip Award for “Best Partnership Alliance”

Publication Name: Press Release

IRVINE, CA and AMSTERDAM, THE NETHERLANDS, FEBRUARY 29, 2012 – Agendia, an innovative molecular cancer diagnostics company, today announced that the company is a recipient of the 2011 Scrip Award for “Best Partnership” for its cooperative alliance between Agendia, AstraZeneca … Continued

Clinical and technical validation of a genomic classifier (ColoPrint) for predicting outcome of patients with stage II colon cancer

Publication Name: 2012 ASCO Gastrointestinal Cancers Symposium, JCO Abstract

Author(s): Josep Tabernero, Victor Moreno, Robert Rosenberg, Ulrich Nitsche, Thomas Bachleitner-Hofmann, Giovanni Lanza, Jeroen van den Akker, Paul Roepman, Iris Simon, Ramon Salazar; Vall d'Hebron University Hospital, Barcelona, Spain; IDIBELL, Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany; Medizinische Universitaet Wien, Vienna, Austria; Department of Experimental and Diagnostic Medicine, Section of Anatomic Pathology, Ferrara, Italy; Agendia BV, Amsterdam, Netherlands; Institut Catala d'Oncologia, Barcelona, Spain

Background: Between 25 and 35% of stage II colon cancer patients will experience a relapse of their disease and may benefit from adjuvant chemotherapy. ColoPrint is a gene expression classifier that can predict disease relapse in patients with early-stage colorectal … Continued